Search
2026
2025
2024
2023
-
Mar 13, 2026
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)Read More
-
Mar 04, 2026
YolTech Therapeutics Reports 24-Week Clinical Data for YOLT-101 in Nature MedicineRead More
-
Feb 19, 2026
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin DeficiencyRead More
-
Feb 02, 2026
YolTech Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation to YOLT-203 for the Treatment of Primary Hyperoxaluria Type 1Read More
-
Nov 19, 2025
YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)Read More
